


Form 1449 (modified)	Docket: 086/002	U.S.S.N.: 10/602,441
INFORMATION DISCLOSURE	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase	
STATEMENT BY APPLICANT	Inventors: Anish Sen Majumdar, <i>et al.</i>	
(Use Several Sheets if Necessary)	Filing Date: June 24, 2003	Group: 1642 1632




U.S. PATENT DOCUMENTS

Examiner/Initial	Document No.	Filing Date	Publication Date	Class/Subclass	Inventors	Title
AS	A 5,583,016	Oct 27/94	Dec 10/96	435/91.3	Villeponteau B et al	Mammalian Telomerase
	B 5,853,719	Apr 30/96	Dec 29/98	424/93.21	Nair SK et al	Methods for Treating Cancers and Pathogen Infections Using Antigen-Presenting Cells Loaded with RNA
	C 6,166,178	Nov 19/97	Dec 26/00	530/324	Cech TR et al	Telomerase Catalytic Subunit
	D 6,261,836	May 9/97	Jul 17/01	435/325	Cech TR et al	Telomerase
	E 6,274,378	Oct 27/98	Aug 14/01	435/377	Steinman RM et al	Methods and Compositions for Obtaining Mature Dendritic Cells
	F 6,300,110	Dec 23/98	Oct 9/01	435/194	Villeponteau B et al	Peptides Related to TPC2 and TPC3, Two Proteins that are Coexpressed with Telomerase Activity
	G 6,306,388	May 6/98	Oct 23/01	424/93.21	Nair SK et al	Methods for Treating Cancers and Pathogen Infections Using Antigen-Presenting Cells Loaded with RNA
	H 6,387,701	Apr 30/99	May 14/02	435/455	Nair SK et al	Method of Identifying Tumor Antigens that Elicit a T-Cell Response
	I 6,440,735	Sep 28/00	Aug 27/02	435/372.2	Gaeta FCA	Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
	J 6,444,650	Mar 31/98	Sep 3/02	514/44	Cech TR et al	Antisense Compositions for Detecting and Inhibiting Telomerase Reverse Transcriptase
	K 6,475,483	Nov 30/99	Nov 5/02	424/93.7	Steinman RM et al	Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens for Treating Autoimmune Diseases
	L 6,475,789	Aug 14/97	Nov 5/02	435/366	Cech TR et al	Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods
	M 6,517,834	Nov 20/00	Feb 11/03	424/94.5	Weinrich SL et al	Purified Telomerase
AS	N 6,545,133	Nov 20/00	Apr 8/03	530/413	Weinrich SL et al	Methods for Purifying Telomerase
	O 6,610,839	Sep 29/99	Aug 26/03	536/24.1	Morin GB et al	Promoter for Telomerase Reverse Transcriptase

Examiner	Date Considered
/Anoop Singh/	05/17/2006

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
PTO-1449 — Page 1

Form 1449 (modified)	Docket: 086/002	U.S.S.N.: 10/602,441
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets if Necessary)	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase Inventors: Anish Sen Majumdar, <i>et al.</i>	
	Filing Date: June 24, 2003	Group: 1642



FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Ref.	Document No.	Publication Date	Jurisdiction	Title	Translation
AS	P	EP 1093381 B1	Aug 20/03	EP	Antigenic Peptides Derived from Telomerase	N/A
	Q	WO 99/27113	Jun 3/99	PCT	Mouse Telomerase Reverse Transcriptase	N/A
	R	WO 99/63945	Dec 16/99	PCT	Vaccination Strategy to Prevent and Treat Cancers	N/A
	S	WO 00/46355	Aug 10/00	PCT	Telomerase Reverse Transcriptase Transcriptional Regulatory Sequences	N/A
	T	WO 00/61766	Oct 19/00	PCT	Telomerase-Specific Cancer Vaccine	N/A
	U	WO 00/73420	Dec 7/00	PCT	Creation of Human Tumorigenic Cells and Uses Therefor	N/A
	V	WO 01/60391	Aug 23/01	PCT	A Universal Vaccine and Method for Treating Cancer Employing Telomerase Reverse Transcriptase	N/A
	W	WO 01/74855	Oct 11/01	PCT	Compositions and Methods for Dendritic Cell-Based Immunotherapy	N/A
	X	WO 02/042445	May 30/02	PCT	Differentiated Cells Suitable for Human Therapy	N/A
	Y	WO 02/042468	May 30/02	PCT	Glycosyltransferase Vectors for Treating Cancer	N/A
✓	Z	WO 02/091999	Nov 21/02	PCT	Treatment for Wounds	N/A
AS	AA	WO 03/038047	May 8/03	PCT	Human Telomerase Reverse Transcriptase as a Class-II Restricted Tumor-Associated Antigen	


OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
AS	AB	Alexander AN et al, Phase I/II Clinical Trial Utilizing a Tumor Cell Vaccine Encoding Xenogeneic Gp100 in Canine Patients with Metastatic Melanoma: Immunological and Clinical Outcomes, AACR Meeting Abstract No. 4158, San Francisco, CA (2002)
	AC	Ayyoub M et al, Lack of Tumor Recognition by hTERT Peptide 540-548-Specific CD8 ⁺ T Cells from Melanoma Patients Reveals Inefficient Antigen Processing, Eur J Immunol 31:2642 (2001)
	AD	Bellone M et al, <i>In Vitro</i> Priming of Cytotoxic T Lymphocytes Against Poorly Immunogenic Epitopes by Engineered Antigen-Presenting Cells, Eur J Immunol 24:2691 (1994)
	AE	Boczkowski D et al, Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells <i>In Vitro</i> and <i>In Vivo</i> , J Exp Med 184:465 (1996)
	AF	Bryan TM et al, Telomerase Reverse Transcriptase Genes Identified in <i>Tetrahymena Thermophila</i> and <i>Oxytricha Trifallax</i> , PNAS USA 95:8479 (1998)
	AG	Disis ML et al, Flt3 Ligand as a Vaccine Adjuvant in Association with HER-2/neu Peptide-based Vaccines in Patients with HER-2/neu-overexpressing Cancers, Blood 99 (8):2845 (2002)
✓	AH	Evans TG et al, The Use of Flt3 Ligand as an Adjuvant for Hepatitis B Vaccination of Healthy Adults, Vaccine 21:322 (2002)
AS	AI	Ferber IA et al, Telomerase Reverse Transcriptase as a Target for <i>In Vivo</i> Gene-Based Cancer Vaccination, Amn Assn Cancer Res Abstract 3007 (2002)

Examiner	/Anoop Singh/	Date Considered	05/17/2006

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
PTO-1449 — Page 2

Form 1449 (modified)	Docket: 086/002	U.S.S.N.: 10/602,441
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase Inventors: Anish Sen Majumdar, <i>et al.</i>	
(Use Several Sheets, if Necessary)	Filing Date: June 24, 2003	Group: 1642



OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
AS	AJ	Ferrone CR et al, H2:lgG Fusion Gene as a Molecular Adjuvant for Xenogeneic DNA Vaccines, Amn Society Gene Therapy Meeting Abstract No. 102, Boston, MA (2002)
	AK	Fong L et al, Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy, J Immunol 167:7150 (2001)
	AL	Folkis M et al, Dendritic Cells Reconstituted with Human Telomerase Gene Induce Potent Cytotoxic T-Cell Response Against Different Types of Tumors, Cancer Gene Therapy 10:239 (2003)
	AM	Fu S et al, Use of Cosmid Adenoviral Vector Cloning System for the <i>In Vitro</i> Construction of Recombinant Adenoviral Vectors, Hum Gene Ther 8:1321 (1997)
	AN	Greener M, Telomerase: The Search for a Universal Cancer Vaccine, Mol Med Today 6:257 (2000)
	AO	Harley CB et al, Telomerase and Cancer, Important Adv Oncol p57 (1996)
	AP	Hawkins WG et al, Xenogeneic DNA Immunization in Melanoma Models for Minimal Residual Disease, J Surg Res 102:137 (2002)
	AQ	Heiser A et al, Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA, J Immunol 166:2953 (2001)
	AR	Hernández J et al, Identification of a Human Telomerase Reverse Transcriptase Peptide of Low Affinity for HLA A2.1 that Induces Cytotoxic T Lymphocytes and Mediates Lysis of Tumor Cells, PNAS 99(19):12275 (2002)
	AS	Kim NW et al, Specific Association of Human Telomerase Activity with Immortal Cells and Cancer, Science 266:2011 (1994)
	AT	Löv A et al, Isolation and Characterization of Human Recombinant Antibodies Endowed with the Antigen-Specific, Major Histocompatibility Complex-Restricted Specificity of T Cells Directed Toward the Widely Expressed Tumor T-Cell Epitopes of the Telomerase Catalytic Subunit, Cancer Res 62:3184 (2002)
	AU	Lichtsteiner SP et al, Telomerase. A Target for Anticancer Therapy, Ann NY Acad Sci 886:1 (1999)
	AV	Minev B et al, Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase in Humans, PNAS 97(9):4796 (2000)
	AW	Miyake S et al, Efficient Generation of Recombinant Adenoviruses Using Adenovirus DNA-Terminal Protein Complex and a Cosmid Bearing the Full-Length Virus Genome, PNAS USA 93:1320 (1996)
	AX	Nair SK et al, Induction of Cytotoxic T Cell Responses and Tumor Immunity Against Unrelated Tumors Using Telomerase Reverse Transcriptase RNA Transfected Dendritic Cells, Nat Med 6(8):1011 (2000)
	AY	Nakamura TM et al, Telomerase Catalytic Subunit Homologs from Fission Yeast and Human, Science 277:955 (1997)
	AZ	Pomer S et al, Tumor Vaccination in Renal Cell Carcinoma with and without Interleukin-2 (IL-2) as Adjuvant. A Clinical Contribution to the Development of Effective Active Specific Immunization, Urolege A 34(3):215 (1995) Abstract
	BA	Simmons SJ et al, GM-CSF as a Systemic Adjuvant in a Phase II Prostate Cancer Vaccine Trial, Prostate 39:291 (1999)
	BB	Steitz J et al, Genetic Immunization of Mice with Human Tyrosinase-Related Protein2: Implications for the Immunotherapy of Melanoma, Int J Cancer 86:89 (2000)
	BC	Su Z et al, Immunological and Clinical Responses in Metastatic Renal Cancer Patients Vaccinated with Tumor RNA-Transfected Dendritic Cells, Cancer Res 63:2127 (2003)
	BD	Tanaka M et al, Induction of a Systemic Immune Response by a Polyvalent Melanoma-Associated Antigen DNA Vaccine for Prevention and Treatment of Malignant Melanoma, Molecular Ther 5(3):291 (2002)
AS	BE	Wolchok JD et al, Of Mice and Men (and Dogs): Xenogeneic DNA Vaccines for Melanoma, Amn Society Gene Therapy Meeting Abstract No. 218, Boston, MA (2002)

Examiner	/Anoop Singh/	Date Considered	05/17/2006

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
PTO-1449 — Page 3